References
- Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015; 45. doi: 10.1111/hepr.12464.
- Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 2007; 6: 37-48. doi: 10.1177/153303460700600106
- Djokic M, Cemazar M, Popovic P, Kos B, Dezman R, Bosnjak M, et al. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. EJSO 2018; 44: 651-7. doi: 10.1016/j. ejso.2018.01.090
- Davalos RV, Mir L, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33: 223. doi: 10.1007/s10439-005-8981-8
- Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg 1998; 227: 559-65. PMID: 9563546
- Rossi S, Garbagnati F, De Francesco I, Accocella F, Leonardi L, Quaretti P, et al. Relationship between the shape and size of radiofrequency induced thermal lesions and hepatic vascularization. Tumori 1999; 85: 128-32. PMID: 10363079
- Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 1998; 9(1 Pt 1): 101-11. PMID: 9468403
- Goldberg SN, Hahn PF, Halpern EF, Fogle RM, Gazelle GS. Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology 1998; 209: 761-7. doi: 10.1148/radiol-ogy.209.3.9844671
- Lu DS, Raman SS, Vodopich DJ, Wang M, Sayre J, Lassman C. Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the “heat sink” effect. AJR Am J Roentgenol 2002; 178: 47-51. doi: 10.2214/ajr.178.1.1780047
- Dollinger M, Beyer LP, Haimerl M, Niessen C, Jung E-M, Zeman F, et al. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience. Diagn Interv Radiol 2015; 21: 471-5. doi: 10.5152/dir.2015.14442
- Frühling P, Nilsson A, Duraj F, Haglund U, Norén A. Single-center non-randomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results. EJSO 2017; 43: 751-7. doi: 10.1016/j.ejso.2016.12.004
- Distelmaier M, Barabasch A, Heil P, Kraemer NA, Isfort P, Keil S, et al. Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins. Radiology 2017; 285: 1023-31. doi: 10.1148/radiol.2017161561
- Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology 2009; 251: 933-40. doi: 10.1148/radiol.2513081740
- Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol 2011; 21: 2584-96. doi: 10.1007/s00330-011-2222-3
- Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012; 23: 727-36. doi: 10.1016/j.jvir.2012.02.012
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-13. doi: 10.1097/01. sla.0000133083.54934.ae
- Sahay A, Sahay N, Kapoor A, Kapoor J, Chatterjee A. Percutaneous image-guided radiofrequency ablation of tumors in inoperable patients - immediate complications and overall safety. Indian J Palliat Care 2016; 22: 67-73. doi: 10.4103/0973-1075.173951
- Carrafiello G, Lagana D, Ianniello A, Dionigi G, Novario R, Recaldini C, et al. Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works. Australas Radiol 2007; 51: 550-4. doi: 10.1111/j.1440-1673.2007.01871.x
- Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20(7 Suppl): S377-90. doi: 10.1016/j.jvir.2009.04.011
- Feher J, Lengyel G. [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. Orv Hetil 2010; 151: 933-40. doi: 10.1556/oh.2010.28900
- Statistisches-Bundesamt. Diagnosedaten der krankenhäuser ab 2000 zweigstelle bonn june 2017 [updated 12. 06. 2017]. Available from: http://www.gbe-bund.de
- Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB 2010; 12: 289-99. doi: 10.1111/j.1477-2574.2010.00181.x.
- Desjardins LA. Hepatocellular carcinoma. Clin J Oncol Nurs 2002; 6: 107-8. doi: 10.1188/02.cjon.107-108
- Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014; 111: 101-6. doi: 10.3238/arztebl.2014.0101.
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019
- Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 4115-27. doi: 10.3748/wjg.v20.i15.4115
- Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. doi: 10.1002/hep.24199
- Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 (Suppl 3): iii1-8. doi: 10.1016/j. jvir.2013.09.005
- Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40: 1043-59. doi: 10.1111/j.1872-034X.2010.00731.x
- Andreano A, Galimberti S, Franza E, Knavel EM, Sironi S, Lee FT, et al. Percutaneous microwave ablation of hepatic tumors: prospective evaluation of postablation syndrome and postprocedural pain. J Vasc Interv Radiol 2014; 25: 97-105. e2. doi: 10.1016/j.jvir.2013.09.005
- Dodd GD, 3rd, Napier D, Schoolfield JD, Hubbard L. Percutaneous radiofrequency ablation of hepatic tumors: postablation syndrome. AJR Am J Roentgenol 2005; 185: 51-7. doi: 10.2214/ajr.185.1.01850051
- Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-51. doi: 10.1148/radiol.2262012198
- Fruhling P, Nilsson A, Duraj F, Haglund U, Noren A. Single-center non-randomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol 2017; 43: 751-7. doi: 10.1016/j.ejso.2016.12.004
- Zeng J, Liu G, Li ZH, Yang Y, Fang G, Li RR, et al. The safety and efficacy of irreversible electroporation for large hepatocellular carcinoma. Technol Cancer Res Treat 2017; 16: 120-4. doi: 10.1177/1533034616676445
- Omary RA, Bettmann MA, Cardella JF, Bakal CW, Schwartzberg MS, Sacks D, et al. Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. J Vasc Interv Radiol 2003; 14(9 Pt 2): S293-5. PMID: 12354820